Articles by Stuart C. Gordon, MD

Late Diagnosis of Hepatitis C Virus Infection, 2014-2016: Continuing Missed Intervention Opportunities
ByAnne C. Moorman, MPH,Jian Xing, PhD,Loralee B. Rupp, MSE,Stuart C. Gordon, MD,Mei Lu, PhD,Philip R. Spradling, MD,Joseph A. Boscarino, PhD,Mark A. Schmidt, PhD,Yihe G. Daida, PhD,Eyasu H. Teshale, MD,for the CHeCS Investigators Late hepatitis C virus infection diagnosis points to a need for earlier screening and treatment before the onset of severe liver disease leading to high cost and diminished outcomes.

Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact
ByZobair Younossi, MD,Stuart C. Gordon, MD,Aijaz Ahmed, MD,Douglas Dieterich, MD,Sammy Saab, MD,Rachel Beckerman, PhD Hepatitis C virus treatment is often restricted in Medicaid patients. This analysis evaluates the clinical and cost impacts of treating all Medicaid patients versus the current status quo.

Real-World Outcomes of Ledipasvir/Sofosbuvir in Treatment-Naïve Patients With Hepatitis C
ByZobair M. Younossi, MD, MPH, FACG, AGAF, FAASLD,Haesuk Park, PhD,Stuart C. Gordon, MD,John R. Ferguson,Aijaz Ahmed, MD,Douglas Dieterich, MD,Sammy Saab, MD, MPH In the treatment of hepatitis C virus, the gap between efficacy and real-world effectiveness narrows with improved tolerability and ease of use.

Hepatitis B Virus Infection Testing and Prevalence Among Asian and Pacific Islanders
ByVinutha Vijayadeva, PhD, MPH,Philip R. Spradling, MD,Anne C. Moorman, BSN, MPH,Loralee B. Rupp, MS,Mei Lu, PhD,Stuart C. Gordon, MD,Emily Henkle, PhD, MPH,Joseph A. Boscarino, PhD, MPH,Eyasu H. Teshale, MD,Cynthia Nakasato, MD* We examined the effect of country of origin on HBV testing and chronic HBV infection prevalence among APIs using data from Kaiser Permanente Hawaii.